Drugs and Pharmaceuticals
Free News Articles Category: Drugs and Pharmaceuticals Industry News Articles
Silver Safety Pyramid Provides Guidelines for Safe Usage of Any Ionic Silver or Colloidal Silver Supplement
freeNewsArticles Story Summary: FORT LAUDERDALE, Fla., Jan. 8 (SEND2PRESS NEWSWIRE) — The Silver Safety Committee today announced its creation of the Silver Safety Pyramid, which is designed to enable anyone to easily determine safe usage levels of any dietary supplement containing silver, typically referred to as ionic silver or colloidal silver….
Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
freeNewsArticles Story Summary: SAN MARINO, Calif., Dec. 16 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation, a leader in tumor-targeted gene delivery systems, has received two additional European patents for the platform targeting technologies and molecular designs that enable precision gene delivery to primary cancers and metastatic lesions that have spread throughout the body. With profound demonstrations of clinical benefit and single-agent-efficacy, as well as overall safety, Epeius Biotech continues to lead the field of clinical gene medicine with the advent of pathotropic targeting….
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma
freeNewsArticles Story Summary: SAN MARINO, Calif., Nov. 20 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November 13-15, 2008. Patients received repeated infusions of Rexin-G i.v. over a period up to 9 months….
Rexin-G Returns to The Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan
freeNewsArticles Story Summary: SAN MARINO, Calif., Oct. 29 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today the expansion of clinical trials using intravenous Rexin-G for pancreatic cancer and breast cancer in Manhattan, New York. Rexin-G is the world’s first tumor-targeted genetic medicine that is designed to seek out and destroy both primary tumors and metastatic cancers that have spread throughout the body….
SELECT TRIAL used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R)
freeNewsArticles Story Summary: FRESNO, Calif., Oct. 29 (SEND2PRESS NEWSWIRE) — Cypress Systems, Inc, a Fresno CA based biotechnology company, emphasizes that the SELECT TRIAL results – that were announced yesterday – used a form of selenium known as selenomethionine. The SELECT TRIAL found no effects of either selenomethionine or vitamin E on the incidence of prostate cancer. See Related Website at cypsystems.com….
Targeting Metastatic Cancer from the Inside: Epeius Biotech Reveals a New Generation of Tools for Medical Gene Delivery
freeNewsArticles Story Summary: SAN MARINO, Calif., Oct. 6 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announced the publication of another landmark paper describing recent technological advances in medical gene delivery. The latest scientific paper, entitled ‘Targeting metastatic cancer from the inside: A new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ,’ was published in the October issue of the International Journal of Oncology….
Epeius Biotechnologies’ Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
freeNewsArticles Story Summary: SAN MARINO, Calif., Sept. 15 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announced that Rexin-G, its lead product in development for metastatic cancer, has been highlighted in a recent NEWS article published by the Journal of the National Cancer Institute (JNCI, Sept. 9, 2008). The article, authored by Vickie Brower, describes recent advances and new approaches in genetic medicine that may succeed where small molecules and proteins have failed….
Epeius Biotechnologies’ Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma
freeNewsArticles Story Summary: SAN MARINO, Calif., July 8 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. Based on several criteria, including the rarity, seriousness, and current lack of effective therapies for metastatic osteosarcoma, as well as the scientific and medicinal merit of Rexin-G, the granting of Orphan Drug Status by the FDA validates the unique clinical development strategy….
Phase I/II Study of Targeted Gene Delivery In Vivo – Intravenous Infusions of REXIN-G
freeNewsArticles Story Summary: SAN MARINO, Calif., May 29 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic bone and soft tissue sarcoma (J Clin Oncol 26: 14509, 2008). Rexin-G is the first and so far only targeted gene therapy vector that has been tested in the clinic (Nature Reviews/Genetics 2007)….
CYNACON / OCuSOFT(R) Announces OCuSOFT(R) Lid Scrub(TM) PLUS Now Available in CVS Pharmacies
freeNewsArticles Story Summary: RICHMOND, Texas (SEND2PRESS NEWSWIRE) — CYNACON / OCuSOFT(R) (OCuSOFT(R), Inc.), a company specializing in ophthalmic research, development and supply to ophthalmologists and optometrists, is pleased to announce that as a convenience to all patients, OCuSOFT(R) Lid Scrub(TM) Plus is now available in CVS pharmacies, nationwide….